GU Cancers 2024 | Hurdles in the development of cellular therapies for kidney cancer

David Aggen, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, comments on barriers in the growth of cellular therapies for kidney cancer. More research is needed to elucidate targetable antigens that are highly expressed on tumors but has limited self-expression. With the development of anti-CD70 cell therapies for urothelial carcinoma, the field of research is promising. This interview took place at the ASCO GU Cancers Symposium 2024 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.